Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079536 | 0.91 | CYP2D6 (0.42) | MEN1KMT2ANPSR1MGLLSIGMAR1 | |
| SCHEMBL6079058 | 0.90 | MGLL (0.42) | MEN1KMT2ANPSR1MGLLSIGMAR1 | |
| SCHEMBL6079116 | 0.87 | MEN1 (0.42) | MEN1KMT2ANPSR1ALDH1A1MAPK1 | |
| SCHEMBL4520059 | 0.81 | CYP2D6 (0.45) | MGLLSIGMAR1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL4534459 | 0.80 | SIGMAR1 (0.44) | MGLLSIGMAR1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL6079452 | 0.78 | MEN1 (0.41) | MEN1KMT2ANPSR1SIGMAR1ALDH1A1 | |
| SCHEMBL4532180 | 0.77 | SIGMAR1 (0.42) | MGLLSIGMAR1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL4527683 | 0.77 | SIGMAR1 (0.42) | MGLLSIGMAR1OPRM1CYP2D6CYP3A4 | |
| SCHEMBL7263014 | 0.77 | ITGB3 (0.41) | MEN1KMT2ANPSR1SIGMAR1CYP2D6 | |
| SCHEMBL6078460 | 0.75 | SIGMAR1 (0.46) | MEN1KMT2ASIGMAR1OPRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| EP-1191028-B1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARM CO LTD (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1191028-A1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | MEN1 631/4885KMT2A 3390/4885NPSR1 2064/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | MEN1 699/4885KMT2A 3342/4885NPSR1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.